Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 30;28:144. doi: 10.1186/s40001-023-01108-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2024

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — The assessment of immunotherapy response by the m7G score signature in the Anti-PD-1 and Anti-PD-L1 cohort. A The Kaplan–Meier curve analysis of high- and low-risk m7G score in the Anti-PD-1 cohort. B The comparison of the m7G score between individuals making complete/partial response (CR/PR) and those who kept a stable/progressive disease (SD/PD). C The proportion of individuals with LGG made complete/partial response (CR/PR) or kept a stable/progressive disease (SD/PD) in high- and low-risk m7G scores. D The Kaplan–Meier curve analysis between high- and low-risk m7G score in the Anti-PD-L1 cohort. E Comparing m7G scores between subjects making CR/PR and the subjects who kept an SD/PD in the Anti-PD-L1 cohort. F The proportion of individuals with LGG made CR/PR or kept an SD/PD in high- and low-risk m7G score of the Anti-PD-L1 cohort